Business Daily Media

Men's Weekly

.

Norgine submits Marketing Authorisation Application to the European Medicines Agency for eflornithine (difluoromethylornithine [DFMO]) in high-risk neuroblastoma

  • Written by PR Newswire
Norgine submits Marketing Authorisation Application to the European Medicines Agency for eflornithine (difluoromethylornithine [DFMO]) in high-risk neuroblastoma

Back to media releasesNext media release

LONDON, Jan. 7, 2025 /PRNewswire/ -- Norgine today announced that it completed its marketing authorisation application filing to European Medicines Agency (EMA) for eflornithine in high-risk neuroblastoma (HRNB). This follows the submissions in April 2024, via Project Orbis, in Australia, Switzerlan...

Australian companies pitching to the world’s wealthiest investors

#CapTech 2025 to bring world investors to Australia’s doorstep  One of Australia’s leading business and capital events is bringing together inves...

Small business backlash builds as RBA’s surcharge ban risks fuelling inflation

Australia’s small business sector has launched a fierce campaign against the Reserve Bank of Australia’s (RBA) proposed ban on debit and credit card...

Australia’s Young Entrepreneurs Redefining Success Through Legacy and Community Impact

A new generation of young Australian small business owners is redefining success, driven by a desire to create a lasting legacy through the positi...

Lessons in AI: How LoanOptions.ai Shows What Smart Adoption Really Looks Like

In a world where many small businesses are still trying to work out how to actually use AI (not just talk about it), Australian fintech LoanOption...

Driving smarter: how car subscription models are redefining mobility and financial flexibility

The world of mobility is changing fast, and car ownership is no longer the default. Across Australia, professionals and businesses alike are seeki...

The Future of Wealth Technology

“You shouldn’t need a large account balance to experience real-time investing. Technology should make that kind of access universal.” For decades...